Ditchcarbon
  • Customers
  1. Organizations
  2. I-Mab Biopharma
Public Profile
Pharmaceutical Preparation Manufacturing
CN
updated 5 months ago

I-Mab Biopharma

Company website

I-Mab Biopharma, a leading biopharmaceutical company headquartered in China, focuses on the discovery and development of innovative therapies for cancer and autoimmune diseases. Founded in 2015, I-Mab has rapidly established itself in the global biopharma landscape, with significant operational presence in both China and the United States. The company is renowned for its robust pipeline of monoclonal antibodies and proprietary drug candidates, which are designed to address unmet medical needs. Notable achievements include strategic partnerships and collaborations that enhance its research capabilities and market reach. With a commitment to advancing healthcare through cutting-edge science, I-Mab Biopharma continues to position itself as a key player in the biopharmaceutical industry, dedicated to improving patient outcomes worldwide.

DitchCarbon Score

How does I-Mab Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

49

Industry Benchmark

I-Mab Biopharma's score of 20 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.

14%

Let us know if this data was useful to you

I-Mab Biopharma's reported carbon emissions

I-Mab Biopharma, headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges available from the company. This lack of data suggests that I-Mab Biopharma may not have established formal commitments to reduce carbon emissions or may not publicly disclose such information at this time. In the context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting science-based targets to align with global climate goals. However, without specific emissions data or commitments from I-Mab Biopharma, it is unclear how the company positions itself within this evolving landscape.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. I-Mab Biopharma's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for I-Mab Biopharma is in CN, which we do not have grid emissions data for.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

I-Mab Biopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Mabwell Therapeutics, Inc.

US
Updated 5 days ago

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

CN
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Pyxis Oncology, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Bio-Thera Solutions, Ltd.

CN
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Exelixis, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250730.5
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy